Grant: Alliance Grants

McMaster researchers in collaboration with clinicians at St. Joseph's Hospital and industry partners at Methapharm Specialty Pharmaceuticals have partnered since 2019 to produce protein-selective RNA-cleaving DNAzymes (RCDs) and associated diagnostic assays that provide simple and rapid detection of eosinophilic asthma. Methapharm is interested in further developing this platform based on the following 4 overarching goals: 1) Improved RCD Selection: We will develop and apply rapid selection methods for new protein and polysaccharide-activated RCDs, which will include optimizing current electrophoresis-based selection protocols and developing an automated magnetic bead-based RCD selection method. These methods will be applied to the development of RCDs for a range of new markers for both chronic and infectious respiratory diseases. 2) Improved Lateral Flow and Flourescence Assays: We will develop RCD-based point-of-care LFD and fluorescence tests that integrate sample processing steps for samples such as blood, throat swabs, nasal secretions, saliva, urine, etc.; integrate key assay steps directly onto LFDs to improve ease of use; implement isothermal DNA amplification steps to reduce assay time and improve detection limits; and develop simple methods for quantification of LFD and fluorescence results using either color cards or handheld readers. 3) Validation of new Assays: We will evaluate LFD and fluorescence assay performance using both spiked samples and appropriate patient samples to generate information on the clinical sensitivity and specificity of the tests for all new RCDs and associated rapid tests. 4) Technology Transfer: We will transfer technology related to any new RCDs or rapid tests to Methpharm, who will work with manufacturers to develop an end product. The outcomes will include a series of rapid tests that are ready for final manufacturing, regulatory approval, and commercialization by our partner.